With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
This article was originally published in PharmAsia News
Executive Summary
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.